STERIS plc

Listed Company

STECIK 0001757898NYSELarge AcceleratedOrthopedic, Prosthetic & Surgical Appliances & SuppliesL2FY ends Mar 31

Period

FY 2026

Revenue

$5.94B

Net Income

$782.30M

Total Assets

$10.74B

Equity

$7.18B

Shares Out

97.60M

Op. Cash Flow

$1.34B

Business

STERIS plc provides products and services that support patient care with an emphasis on infection prevention and sterile processing for healthcare and life science customers. It offers consumable infection‑prevention products (detergents, disinfectants, endoscopy accessories, barrier products), capital equipment (sterilizers, washers, surgical tables, automated endoscope reprocessors), repair, maintenance and outsourced reprocessing services, laboratory testing, and connectivity/OR integration solutions. The company operates through three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its products and services are sold and serviced globally across the Americas, Europe and Asia via direct sales, clinical specialists, distributors, and service networks.

Summary from filing dated 2025-05-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Revenues:	—	—	—
Total revenues	5,936	5,460	5,139
Cost of revenues:	—	—	—
Cost of revenues	3,309	3,057	2,921
Gross Profit	2,627	2,403	2,218
Operating expenses:	—	—	—
Selling, general, and administrative	1,408	1,334	1,252
Research and development	113	108	104
Litigation Settlement, Loss	0	48	0
Restructuring Costs	4	46	26
Total operating expenses	1,525	1,536	1,382
Income (loss) from operations	1,102	867	836
Non-operating expenses, net:	—	—	—
Interest expense	61	86	144
Interest income and miscellaneous expense	10	8	11
Other expense (income), net	−4	7	0
Total non-operating expenses, net	−54	−70	−133
Income (loss) before income tax expense (benefit)	1,047	796	703
Income tax expense (benefit)	262	185	150
Income from continuing operations, net of income tax	785	612	553
Income (loss) from discontinued operations, net of income tax	0	5	−173
Net income	785	616	380
Less: Net income attributable to noncontrolling interests	3	1	2
Net income attributable to shareholders	782	615	378
Net income (loss) per common share	—	—	—
Income (Loss) from Continuing Operations, Per Basic Share	7.97	6.19	5.58
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	0	0.05	−1.75
Earnings Per Share, Basic	7.97	6.24	3.83
Income (Loss) from Continuing Operations, Per Diluted Share	7.93	6.16	5.55
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	0	0.05	−1.74
Earnings Per Share, Diluted	7.93	6.2	3.81
Cash dividends declared per common share outstanding	2.46	2.23	2.03

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31
Assets	—	—
Current assets:	—	—
Cash and cash equivalents	440	172
Accounts receivable (net of allowances of $24,354 and $22,984, respectively)	1,093	1,044
Inventories, net	632	581
Prepaid expenses and other current assets	230	204
Total current assets	2,395	2,001
Property, plant, and equipment, net	2,161	1,957
Operating Lease, Right-of-Use Asset	155	156
Goodwill	4,195	4,096
Intangible Asset, Excluding Goodwill, after Accumulated Amortization	1,620	1,854
Other assets	211	83
Assets	10,737	10,147
Liabilities and equity	—	—
Current liabilities:	—	—
Accounts payable	339	281
Accrued Income Taxes, Current	29	22
Accrued payroll and other related liabilities	221	193
Capital Lease Obligations, Current	36	34
Short-term Debt	119	125
Accrued expenses and other	402	368
Total current liabilities	1,145	1,022
Long-term indebtedness	1,813	1,919
Deferred income taxes, net	391	404
Capital Lease Obligations, Noncurrent	120	125
Other Liabilities, Noncurrent	72	62
Total liabilities	3,540	3,531
Commitments and contingencies (see note 10)	—	—
Ordinary shares, with $0.001 par value; 500,000 shares authorized; 98,301 and 98,883 ordinary shares issued and outstanding, respectively	4,281	4,420
Retained earnings	3,016	2,475
Accumulated other comprehensive income	−113	−292
Total shareholders' equity	7,184	6,603
Noncontrolling interest	14	12
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	7,197	6,616
Total liabilities and equity	10,737	10,147

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Income from continuing operations, net of income tax	785	616	380
Adjustments to reconcile net (loss) income to net cash provided by operating activities:	—	—	—
Depreciation, depletion, and amortization	487	476	565
Deferred income taxes	−17	−77	−131
Share-based compensation	62	57	57
Loss on the disposal of property, plant, equipment, and intangibles, net	−4	−6	−25
Loss on classification as held for sale	0	0	206
Gain (Loss) on Disposition of Business And Equity Investments, Net	300,000	−6	−300,000
Amortization of inventory fair value adjustments	0	0	5
Other items	6	4	−12
Changes in operating assets and liabilities, net of effects of acquisitions:	—	—	—
Changes in operating assets and liabilities:	—	—	—
Accounts receivable, net	25	29	128
Inventories, net	24	−73	38
Other current assets	23	50	2
Accounts payable	51	34	−19
Accruals and other, net	48	39	40
Net cash provided by operating activities	1,341	1,148	973
Investing activities:	—	—	—
Purchases of property, plant, equipment, and intangibles, net	369	370	360
Proceeds from the sale of property, plant, equipment, and intangibles	11	9	7
Proceeds from Divestiture of Businesses	0	815	10
Proceeds from Sale of Other Investments	0	0	4
Payments to Acquire Investments	134	11	2
Investments in businesses, net of cash acquired	20	54	546
Net cash used in investing activities	−513	389	−887
Financing activities:	—	—	—
Repayments of Secured Debt	0	638	60
Payments for Repurchase of Private Placement	125	80	0
Proceeds Under Credit Facility, net	3	−446	182
Amortization of Financing Costs	0	2	0
Payments of Merger Related Costs, Financing Activities	400,000	400,000	6
Repurchases of ordinary shares	236	211	12
Cash dividends paid to common shareholders	242	220	201
Payments to Noncontrolling Interests	1	2	2
Proceeds from Noncontrolling Interests	0	3	3
Proceeds from (Payment for) Other Financing Activity	33	26	11
Net cash (used in) provided by financing activities	−568	−1,572	−85
Effect of exchange rate changes on cash and cash equivalents	7	200,000	−2
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	268	−35	−1
Cash and cash equivalents at end of period	—	—	—
Cash and cash equivalents at end of period	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro